Paper Details

  1. Home
  2. Paper Details

Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.

Author: MesaR A, PetittR M, SilversteinM N, SolbergL A, TefferiA

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Anagrelide, an oral drug, has been shown to effectively reduce platelet levels in patients with essential thrombocythemia (ET). More than 90% of ET patients respond to anagrelide with a median maintenance dose of 2-2.5 mg/day. Common side effects include headache, fluid retention, tachycardia, and arrhythmias.
Paper Details　
Original Abstract of the Article :
Anagrelide is an oral imidazoquinazoline agent with an anti-cyclic AMP phosphodiesterase activity and inhibits platelet aggregation in both humans and animals. In addition, it has in humans a species-specific platelet-lowering activity observed at dose levels lower than those required to inhibit pla...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1055/s-2007-996112

データ提供：米国国立医学図書館（NLM）

Anagrelide: A New Hope for Essential Thrombocythemia

The realm of hematology constantly seeks innovative solutions for challenging blood disorders. This study delves into the potential of anagrelide, a promising new drug for treating essential thrombocythemia (ET), a condition characterized by excessive platelet production. The researchers explored the mechanism of action, efficacy, toxicity, and current indications of anagrelide, shedding light on its potential to manage this complex disorder. The findings suggest that anagrelide holds significant promise as a new treatment option for patients with ET, offering a beacon of hope in this often-challenging field.

Promising Results: Anagrelide Shows Its Worth

This research suggests that anagrelide is a potent platelet-reducing agent in essential thrombocythemia (ET) and related disorders. More than 90% of patients with ET respond to anagrelide, demonstrating its effectiveness.

Navigating the Desert of Thrombocythemia: Anagrelide as a Guide

The implications of this study are significant for patients with ET. It offers a new therapeutic avenue with a high response rate, providing a glimmer of hope for improved management of this disorder. Just as a camel navigating the vast desert needs a reliable guide, patients with ET can find solace in the promising potential of anagrelide.

Dr.Camel's Conclusion

Anagrelide emerges as a promising new drug for treating essential thrombocythemia, offering a potential solution for a complex blood disorder. This research provides valuable insights into the mechanism of action, efficacy, and safety of anagrelide, paving the way for improved treatment options and a more optimistic outlook for patients with ET.

Date :
  1. Date Completed 1997-10-30
  2. Date Revised 2016-11-24
Further Info :

Pubmed ID

9263355

DOI: Digital Object Identifier

10.1055/s-2007-996112

Related Literature

Article Analysis
・Side Effects of anagrelide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.